Clinical Trials Directory
Participants will take part in the main study, including screening, treatment, and follow up, for about 3 years. After receiving the study treatment, they will continue in a long term safety monitoring program for an additional 15 years so researchers can track their health and any delayed side effects.
In this study, emergency room doctors and advanced practice providers will take part in special training to learn how to use heart and lung ultrasound. The training includes lessons and hands on practice using simulations. The training program is created together with hospital leaders and ultrasound experts. After the training, participants will use ultrasound during normal patient care to check the hearts and lungs of patients who have acute heart failure, following standard care guidelines.
Participants will attend 3 in person visits over about 1 to 2 weeks. At each visit, they will complete an exercise test on a stationary bike while researchers monitor heart activity. Participants will also complete questionnaires and provide blood samples, either by fingerstick or through a small IV during exercise.
We are doing this study to find out if an experimental drug called eplontersen (the study drug) is safe and helpful for people with cardiac amyloidosis. We are enrolling people who previously participated in a clinical trial for this drug called the CardioTTRansform study (ION-682884-CS2).
This study does not test a new treatment. People will continue to receive their regular transplant care. The study looks at blood and DNA samples to learn if a blood test called AlloHeme can help doctors find signs that a disease may come back after a transplant. For transplant recipients, the study lasts about two years. They will give a blood sample before the transplant and then provide blood samples and a cheek swab during follow up visits after the transplant. Researchers will compare the donor and recipient DNA samples to look for early signs that the disease might return. For donors, participation is much shorter. They will provide one small blood sample for DNA testing during a single study visit that lasts about 30 minutes. After that sample is collected, their participation in the study is complete.
Participants will be followed for up to 10 years. Information from their pediatric rheumatology clinic visits will be added to a study database at least twice each year. Participants or their parents or guardians will also complete questionnaires during the study.
We are doing this study to find out if an experimental drug called CAP-100 (study drug) is a safe and effective treatment for people who have CLL or SLL that is not responding to standard treatments. We also want to know what dose of this study drug works best.
If people join this study, they will be placed into one of two groups by chance. Everyone will receive a computer based treatment designed to help them stop using cannabis. The treatment includes seven sessions, and a study team member will call each week to provide support and check on progress. Some participants will also receive an extra program called mobile contingency management. In this program, participants will record themselves taking saliva tests and upload the videos to the study website. If the tests show they have not used cannabis, they can earn money as a reward. After the treatment period, participants will complete five follow up sessions. Researchers want to learn which approach works best to help people stop using cannabis and maintain their progress over time.